Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
MOUNTAIN VIEW, Calif., Feb. 27, 2018 -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company plans to participate in the upcoming 30th Annual Roth Conference in Orange County, CA.
IRIDEX’s management is scheduled to present on Tuesday, March 13, 2018 at 11:00am PT. Interested parties may access a live and archived webcast of the presentation at www.IRIDEX.com.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
